FDA won't demand new trial for ZymoGenetics therapy

ZymoGenetics says that the FDA will not need another clinical trial for rhThrombin, an experimental spray to reduce bleeding during surgery. Company officials say the decision by the FDA could reduce the time it takes to get the therapy to market by 18 months and significantly reduce its development costs. The agency accepted the therapy for review in February and is scheduled to give a decision by mid-October. The therapy is a recombinant form of human thrombin. Currently, the only stand-alone thrombin available in the U.S. is derived from bovine blood. Novo Nordisk has a 32 percent stake in ZymoGenetics.

- here's the release
- read the AP report on the FDA's decision

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.